| FIRST AUTHOR INDEX |
| Last Name |
First Name |
No. |
Title |
| Berk |
Michael |
SL-1
|
Oxidative and immune biomarkers as targets for novel therapies |
| Phillips |
Anthony G. |
SL-2 |
Stress and cognition: A critical role for the prefrontal cortex |
| Zohar |
Joseph |
N-SL |
DSM 5 and RDOC conceptual consideration and implication on diagnosis and treatment of Anxiety Disorders |
| Yatham |
Lakshmi N. |
CL-1 |
Promises of DSM.5 and the Current Realities: Implications for Bipolar Disorder Diagnosis and Treatment |
| REIJI |
YOSHIMURA |
C-S3-2 |
Predictions for responses to antidepressants: view from catecholamines, cytokines, and brain-derived neurotrophic factor |
| HIDENORI |
YAMASUE |
C/N-S5-2 |
Development of therapeutics for core symptoms of autism spectrum disorders: Clinical trials of intranasal oxytocin |
| TERUO |
HAYASHI |
N-S2-1 |
Molecular function of the endoplasmic reticular chaperone sigma-1 receptor |
| SHIZUKA |
SHIMABUKURO |
N-S4-4 |
ADHD: Where basic science meets clinical practice |
| TOMOYUKI |
FURUYASHIKI |
N-S8-4 |
Repeated stress-induced changes in dopaminergic functions in the medial prefrontal cortex in mice |
| SHIN |
ONO |
EN-2 |
The prevalence of glucose intolerance in Japanese schizophrenic patients with a normal fasting glucose level |
| YUTARO |
SUZUKI |
EN-3 |
Differences in plasma prolactin levels in patients with schizophrenia treated on monotherapy with five second-generation antipsychotics |
| MASAYA |
YANAGI |
AB-2 |
A potassium channel, Kv3.1, is reduced in schizophrenia and normalized with antipsychotic drugs; a possible new drug target for schizophrenia |
| Berk |
Michael |
LS2-D |
Preventing depressive episodes in bipolar disorder: Maintenance therapy |
| Yatham |
Lakshmi N. |
LS2-E |
Recent Advances in Diagnosis and Treatment of Bipolar Disorder |
| Zohar |
Joseph |
LS3-B |
Science and nomenclature - Could infusion of neuroscience change an outdated psychotropic classification? An update |
| Phillips |
Anthony G. |
ES2-B |
Prospects for more effective treatment of schizophrenia through innovations in neuropsychopharmacology |
| TAKASHI |
WATANABE |
O1-C5 |
5-HTTLPR genotype is the determinant of the therapeutic response and discontinuation of paroxetine initial treatment in panic disorder, not in major depressive disorder |
| KOICHI |
NISHIJIMA |
O1-D2 |
Temporal changes in serum creakine kinase concentration and degree of muscle rigidity in 24 patients with neuroleptic malignant syndrome |
| KAZUNARI |
YOSHIDA |
O1-D3 |
Abnormal involuntary movement and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data |
| YUYA |
MIZUNO |
O1-D5 |
Polypharmacy to Counteract Antipsychotic-Induced Weight Gain and Metabolic Adverse Effects in Schizophrenia: A Systematic Review and Metaanalysis |
| TSUYOSHI |
MIYAOKA |
O3-C2 |
Efficacy and Safety of Yokukansan (TJ-54) in Treatment-Resistant Schizophrenia: A PANSS five-factor analysis |
| MUHAMMAD RASHEDUL |
ISLAM |
O3-D1 |
Rivastigmine improves the hippocampal neurogenesis and anti-depressivelike behaviors in olfactory bulbectomized mice |
| KENJI |
HASHIMOTO |
O3-D3 |
Role of BDNF-TrkB signaling in the inflammation-induced depression |
| SHIHO |
KITAOKA |
O3-D4 |
A role for neuron-microglia interaction through the innate immune signaling in emotional changes caused by repeated social defeat stress in mice |
| SHIGEKI |
MORIGUCHI |
O3-E5 |
Sigma-1 receptor stimulation improves depressive-like behaviors in CaMKIV null mice |
| MANABU |
FUCHIKAMI |
O3-E6 |
Pharmacological and optogenetic characterization of the critical PFC subregions underlying the rapid antidepressant actions of ketamine |
| KATSUTOSHI |
YOKOYAMA |
O3-C7 |
Milnacipran influences the indexes of I-metaiodobenzylguanidine (MIBG) scintigraphy in elderly depressed patients |
| YUKIE |
KAWAHARA |
O3-D12 |
Food reward-sensitive interaction of ghrelin and opioid receptor pathways in mesolimbic dopamine system |
| JUNZO |
WATANABE |
CNP1-10 |
The lipid profiles in Japanese patients with schizophrenia treated with antipsychotic agents |
| TARO |
KISHI |
CNP1-22 |
Efficacy and Tolerability of Perospirone in Schizophrenia: A Systematic Review and Meta-analysis of Randomized Controlled Trials |
| TARO |
KISHI |
CNP1-23 |
Augmentation of Antipsychotic Drug Action by Azapirone Serotonin1A Receptor Partial Agonists: A Meta-analysis |
| Yuki |
Matsuda |
CNP1-24 |
Updated Meta-analysis of NMDA Receptor Antagonists Interventions in Schizophrenia |
| TAKASHI |
TSUBOI |
CNP1-26 |
Predicting plasma concentration of olanzapine associated with dosage change: a population pharmacokinetic study |
| MASAKI |
KATO |
CNP1-34 |
Effect of brain volume-related SNPs of GSK3B gene on SSRI/SNRI treatment response in major depressive disorder |
| SHIGERU |
MORINOBU |
CNP1-35 |
Searching for epigenetic biomarkers in major depression: focusing on the serotonin signal transduction |
| WAKAKO |
NAKANO |
CNP1-61 |
Aripiprazole improves various cognitive and behavioral impairments after traumatic brain injury: a case report |
| MIZUKI |
ASANO |
CNP1-68 |
Effects of Ramelteon on Refractory Behavioral and Psychological Symptoms of Dementia in Alzheimer Disease |
| YUMIKO |
AKAMINE |
CNP1-77 |
Different effects of two transporting inhibitors, itraconazole and cimetidine on paliperidone enantiomers pharmacokinetics |
| RYOICHI |
SADAHIRO |
CNP1-78 |
Relationship between the C3435T MDR1 polymorphism and endogenous steroid hormones in healthy subjects |
| YUTARO |
SUZUKI |
CNP2-3 |
Changes in PR and QTc intervals after switching from olanzapine to risperidone in patients with stable schizophrenia |
| EIJI |
HARADA |
CNP2-34 |
Duloxetine: Effects of Dosing and Titration on Treatment Discontinuation in Patients with Major Depression |
| NORIAKI |
SAGATA |
NP2-43 |
A single-shot minocycline inhibits methamphetamine-induced behavioral sensitization in mice |
| EIICHI |
TAIRA |
NP2-51 |
Induction of endoplasmic reticulum stress related gene CHOP/Gadd153/ ddit3 in dopaminergic cells by methamphetamine |
| KAZUTAKA |
OHI |
NP2-61 |
Impacts of the genome-wide association mega-analysis supported variants on brain morphology in schizophrenia; a comprehensive VBM analysis |
| HIDENAGA |
YAMAMORI |
NP2-62 |
Plasma levels of mature brain-derived neurotrophic factor (BDNF) and matrix metalloproteinase-9 (MMP-9) in treatment-resistant schizophrenia treated with clozapine |
| MICHIKO |
FUJIMOTO |
NP2-66 |
Eye movement abnormalities in patients with schizophrenia |
| TATSUO |
SHIBA |
NP2-74 |
Involvement of autophagy signaling in Li2CO3-induced enhancement of the proliferation of neural stem/progenitor cells derived from the subventricular zone of adult mice |
| KOJI |
OHIRA |
NP2-82 |
Chronic fluoxetine treatment decreases parvalbumin and perineuronal nets in interneurons of frontal cortex and hippocampus of adult mice |
| AKIRA |
NAKAJIMA |
NP2-111 |
Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces oxidative stress and tau hyperphosphorylation in SAMP8 mice |
| YUKI |
KISHIKAWA |
NP2-113 |
Effects of low-dose methylphenidate on attention-deficit hyperactivity disorder (ADHD)-like behaviors in the spontaneously hypertensive rat, an animal model of ADHD |
| RYOTA |
SHINOHARA |
NP2-116 |
A role for dopamine D1 receptor in the medial prefrontal cortex in regulating stress susceptibility in mice |
| SATOKO |
HATTORI |
NP2-117 |
In vivo evaluation of CNS in alpha-CaMKII heterozygous knockout mice using manganese-enhanced magnetic resonance imaging |
| SATOSHI |
KUCHIIWA |
NP2-121 |
A novel semi-automated method for measurement and quantitative analysis of aggressive biting behavior in male and female mice |
| TETSUYA |
HASHIMOTO |
NP2-141 |
Increased hippocampal quinone reductase 2 in Alzheimer's disease |
| RIE |
ISHIKAWA |
NP2-144 |
Erasure of hippocampus-dependent fear memory by NMDA-glutamate receptor antagonist memantine |
| RYO |
FUKUMORI |
NP2-146 |
The role of uncoupling protein-2 in glutamate neurotoxicity with ischemia |
| YASUNORI |
MATSUDA |
NP2-155 |
Association of the clinical subtype and etiology for delirium with the outcome after risperidone monotherapy in patients having cancer |
